Looks Health (534422)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at a 62% discount to book value: P/B of 0.38 versus book value of ₹15.02
• Piotroski F-score of 6/9 points to moderate balance-sheet health
• Tiny ₹6 Cr market cap could attract control or restructuring interest if assets are realizable
• No dividend and no sales growth means expectations are low, reducing downside if assets are worth book

Concerns

• Latest quarter sales and net profit are both ₹0 Cr, indicating no meaningful operating business
• ROE of 1.38% and ROCE of 0.40% show capital is generating almost no return
• P/E of 49.57 and 133% profit growth are misleading given the negligible earnings base
• Promoter holding is N/A and FairStock Score is INSUFFICIENT_DATA, so governance and disclosure are unclear

AI Analysis

Looks Health is precisely the kind of cigar butt that fascinates bargain hunters: ₹5.73 per share against ₹15.02 book value, a 62% discount. But in Graham's world, a low price-to-book is only a starting point, not a conclusion. The hardest evidence is missing — latest quarter sales are ₹0 Cr and net profit is ₹0 Cr. A business that earns almost nothing on its assets is not a business; it is a balance sheet waiting for a catalyst. ROE of 1.38% and ROCE of 0.40% confirm that capital is sitting idle. The reported 133% profit growth and 49.57 P/E are statistical illusions, because the earnings base is negligible and the direction can reverse with one expense item. The Piotroski F-score of 6/9 suggests the company is not in immediate distress, but that score says little about future economics. No dividend, no sales growth, and promoter holding not disclosed leave an information vacuum. A P/B of 0.38 can be rewarding if book value is real — land, investments, receivables — and shareholders can force realization. It can also be a trap if the book is inflated or tied up in non-earning, illiquid assets. With market cap at ₹6 Cr, this is micro-cap territory where operating costs and one-off events swamp fundamentals. I cannot call it a wonderful business; therefore it is not a wonderful investment. It is an asset play, and only for those who can independently verify the assets and the intentions of control holders. I will watch, not buy, until evidence of value-unlocking appears.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer